Design Therapeutics, Inc. 8-K

What Happened

• Design Therapeutics, Inc. (DSGN) filed a Current Report on Form 8-K dated April 28, 2026 announcing its financial results for the three months ended March 31, 2026. The company issued a press release with those results, attached as Exhibit 99.1 to the filing.
• On the same date the company published an updated corporate presentation for use with investors and analysts (attached as Exhibit 99.2) and said the presentation will be posted on its website in Investors → News & Events → Events & Presentations, accompanied by a recorded narrative.

Key Details

• Filing date: April 28, 2026; period covered: three months ended March 31, 2026 (Q1 2026).
• Exhibits: 99.1 = press release with financial results; 99.2 = updated company presentation (to be posted on the company website with a recorded narrative).
• Disclosure status: The press release and presentation are being furnished (not “filed”) under the Exchange Act and are not incorporated by reference into other filings.
• Form 8-K signed by Pratik Shah, Ph.D., President, CEO and Chairperson, dated April 28, 2026.

Why It Matters

• This 8-K delivers Design Therapeutics’ latest quarterly results and refreshed investor materials — essential sources for investors seeking current revenue, expense, cash position, program updates, or management commentary for Q1 2026.
• Investors should review the attached press release (Exhibit 99.1) and updated presentation (Exhibit 99.2 on the company website) for the specific financial figures and any operational or strategic updates disclosed.